非アルコール性脂肪性肝炎（NASH）の世界市場（～2026年）

• 英文タイトル：Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY03996 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は非アルコール性脂肪性肝炎（NASH）のグローバル市場について調査・分析したレポートです。種類別（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E）市場規模、用途別（病院薬局、オンラインプロバイダー、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別非アルコール性脂肪性肝炎（NASH）の競争状況、市場シェア ・世界の非アルコール性脂肪性肝炎（NASH）市場：種類別市場規模 2015年-2020年（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E） ・世界の非アルコール性脂肪性肝炎（NASH）市場：種類別市場規模予測 2021年-2026年（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E） ・世界の非アルコール性脂肪性肝炎（NASH）市場：用途別市場規模 2015年-2020年（病院薬局、オンラインプロバイダー、小売薬局） ・世界の非アルコール性脂肪性肝炎（NASH）市場：用途別市場規模予測 2021年-2026年（病院薬局、オンラインプロバイダー、小売薬局） ・北米の非アルコール性脂肪性肝炎（NASH）市場分析：米国、カナダ ・ヨーロッパの非アルコール性脂肪性肝炎（NASH）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの非アルコール性脂肪性肝炎（NASH）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の非アルコール性脂肪性肝炎（NASH）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの非アルコール性脂肪性肝炎（NASH）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Tobira Therapeutics、Cadila Healthcare、Conatus Pharmaceuticals、Galmed Pharmaceuticals、Gemphire Therapeutics、Genfit、Gilead Sciences、Intercept Pharmaceuticals、Novartis International、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Market Analysis and Insights: Global Nonalcoholic Steatohepatitis (NASH) Market
The global Nonalcoholic Steatohepatitis (NASH) market size is projected to reach US$ 3159 million by 2026, from US$ 2086.6 million in 2020, at a CAGR of 46.7%% during 2021-2026.

Global Nonalcoholic Steatohepatitis (NASH) Scope and Market Size
Nonalcoholic Steatohepatitis (NASH) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Tobira Therapeutics
Cadila Healthcare
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Gemphire Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
Novartis International
Takeda

Market segment by Type, the product can be split into
Obeticholic acid（OCA）
Selonsertib
Emricasan
GR-MD-02
IMM-124E
Market segment by Application, split into
Hospital Pharmacy
Online Provider
Retail Pharmacy

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
1.4 Market by Type
1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Obeticholic acid（OCA）
1.4.3 Selonsertib
1.4.4 Emricasan
1.4.5 GR-MD-02
1.4.6 IMM-124E
1.5 Market by Application
1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacy
1.5.3 Online Provider
1.5.4 Retail Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2015-2026)
2.2 Global Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Share by Regions (2015-2020)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Nonalcoholic Steatohepatitis (NASH) Market Growth Strategy
2.3.6 Primary Interviews with Key Nonalcoholic Steatohepatitis (NASH) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Market Size
3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2015-2020)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2015-2020)
3.1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2019
3.3 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.4 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
3.5 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2015-2020)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
6.2 Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2019-2020)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
7.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Europe (2019-2020)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

8 China
8.1 China Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
8.2 Nonalcoholic Steatohepatitis (NASH) Key Players in China (2019-2020)
8.3 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
8.4 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
9.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Japan (2019-2020)
9.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
9.4 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
10.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
10.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

11 India
11.1 India Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
11.2 Nonalcoholic Steatohepatitis (NASH) Key Players in India (2019-2020)
11.3 India Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
11.4 India Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2020)
12.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Central & South America (2019-2020)
12.3 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
12.4 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Tobira Therapeutics
13.1.1 Tobira Therapeutics Company Details
13.1.2 Tobira Therapeutics Business Overview
13.1.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
13.1.4 Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020))
13.1.5 Tobira Therapeutics Recent Development
13.2 Cadila Healthcare
13.2.1 Cadila Healthcare Company Details
13.2.2 Cadila Healthcare Business Overview
13.2.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Introduction
13.2.4 Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.2.5 Cadila Healthcare Recent Development
13.3 Conatus Pharmaceuticals
13.3.1 Conatus Pharmaceuticals Company Details
13.3.2 Conatus Pharmaceuticals Business Overview
13.3.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
13.3.4 Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.3.5 Conatus Pharmaceuticals Recent Development
13.4 Galmed Pharmaceuticals
13.4.1 Galmed Pharmaceuticals Company Details
13.4.2 Galmed Pharmaceuticals Business Overview
13.4.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
13.4.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.4.5 Galmed Pharmaceuticals Recent Development
13.5 Gemphire Therapeutics
13.5.1 Gemphire Therapeutics Company Details
13.5.2 Gemphire Therapeutics Business Overview
13.5.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
13.5.4 Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.5.5 Gemphire Therapeutics Recent Development
13.6 Genfit
13.6.1 Genfit Company Details
13.6.2 Genfit Business Overview
13.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
13.6.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.6.5 Genfit Recent Development
13.7 Gilead Sciences
13.7.1 Gilead Sciences Company Details
13.7.2 Gilead Sciences Business Overview
13.7.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Introduction
13.7.4 Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.7.5 Gilead Sciences Recent Development
13.8 Intercept Pharmaceuticals
13.8.1 Intercept Pharmaceuticals Company Details
13.8.2 Intercept Pharmaceuticals Business Overview
13.8.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
13.8.4 Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.8.5 Intercept Pharmaceuticals Recent Development
13.9 Novartis International
13.9.1 Novartis International Company Details
13.9.2 Novartis International Business Overview
13.9.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Introduction
13.9.4 Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.9.5 Novartis International Recent Development
13.10 Takeda
13.10.1 Takeda Company Details
13.10.2 Takeda Business Overview
13.10.3 Takeda Nonalcoholic Steatohepatitis (NASH) Introduction
13.10.4 Takeda Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020)
13.10.5 Takeda Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Nonalcoholic Steatohepatitis (NASH) Key Market Segments
Table 2. Key Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
Table 3. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Obeticholic acid（OCA）
Table 6. Key Players of Selonsertib
Table 7. Key Players of Emricasan
Table 8. Key Players of GR-MD-02
Table 9. Key Players of IMM-124E
Table 10. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2015-2020)
Table 14. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Nonalcoholic Steatohepatitis (NASH) Market Growth Strategy
Table 20. Main Points Interviewed from Key Nonalcoholic Steatohepatitis (NASH) Players
Table 21. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2015-2020) (Million US$)
Table 22. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players (2015-2020)
Table 23. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2019)
Table 24. Global Nonalcoholic Steatohepatitis (NASH) by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
Table 27. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Type (2015-2020)
Table 31. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2021-2026)
Table 32. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Application (2015-2020)
Table 33. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 34. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Application (2021-2026)
Table 35. North America Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 37. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 38. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 39. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 40. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 41. Europe Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 43. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 45. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 47. China Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 48. China Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 49. China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 50. China Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 51. China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 52. China Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 53. Japan Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 55. Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 57. Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 61. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 63. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 65. India Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 66. India Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 67. India Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 68. India Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 69. India Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 70. India Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Nonalcoholic Steatohepatitis (NASH) Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Nonalcoholic Steatohepatitis (NASH) Market Share (2019-2020)
Table 73. Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2015-2020)
Table 75. Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2015-2020)
Table 77. Tobira Therapeutics Company Details
Table 78. Tobira Therapeutics Business Overview
Table 79. Tobira Therapeutics Product
Table 80. Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 81. Tobira Therapeutics Recent Development
Table 82. Cadila Healthcare Company Details
Table 83. Cadila Healthcare Business Overview
Table 84. Cadila Healthcare Product
Table 85. Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 86. Cadila Healthcare Recent Development
Table 87. Conatus Pharmaceuticals Company Details
Table 88. Conatus Pharmaceuticals Business Overview
Table 89. Conatus Pharmaceuticals Product
Table 90. Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 91. Conatus Pharmaceuticals Recent Development
Table 92. Galmed Pharmaceuticals Company Details
Table 93. Galmed Pharmaceuticals Business Overview
Table 94. Galmed Pharmaceuticals Product
Table 95. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 96. Galmed Pharmaceuticals Recent Development
Table 97. Gemphire Therapeutics Company Details
Table 98. Gemphire Therapeutics Business Overview
Table 99. Gemphire Therapeutics Product
Table 100. Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 101. Gemphire Therapeutics Recent Development
Table 102. Genfit Company Details
Table 103. Genfit Business Overview
Table 104. Genfit Product
Table 105. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 106. Genfit Recent Development
Table 107. Gilead Sciences Company Details
Table 108. Gilead Sciences Business Overview
Table 109. Gilead Sciences Product
Table 110. Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 111. Gilead Sciences Recent Development
Table 112. Intercept Pharmaceuticals Business Overview
Table 113. Intercept Pharmaceuticals Product
Table 114. Intercept Pharmaceuticals Company Details
Table 115. Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 116. Intercept Pharmaceuticals Recent Development
Table 117. Novartis International Company Details
Table 118. Novartis International Business Overview
Table 119. Novartis International Product
Table 120. Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 121. Novartis International Recent Development
Table 122. Takeda Company Details
Table 123. Takeda Business Overview
Table 124. Takeda Product
Table 125. Takeda Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2015-2020) (Million US$)
Table 126. Takeda Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2020 VS 2026
Figure 2. Obeticholic acid（OCA） Features
Figure 3. Selonsertib Features
Figure 4. Emricasan Features
Figure 5. GR-MD-02 Features
Figure 6. IMM-124E Features
Figure 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Online Provider Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions: 2020 VS 2026
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2019
Figure 17. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2019
Figure 19. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed

---